Galera Therapeutics, Inc. (GRTX)
- Previous Close
0.1908 - Open
0.1946 - Bid --
- Ask 0.1945 x 400
- Day's Range
0.1880 - 0.1970 - 52 Week Range
0.0850 - 3.5900 - Volume
351,985 - Avg. Volume
2,016,917 - Market Cap (intraday)
10.552M - Beta (5Y Monthly) 2.17
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3300 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.50
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
www.galeratx.comRecent News: GRTX
Performance Overview: GRTX
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GRTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GRTX
Valuation Measures
Market Cap
10.39M
Enterprise Value
-6.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.14
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-83.63%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-59.08M
Diluted EPS (ttm)
-1.3300
Balance Sheet and Cash Flow
Total Cash (mrq)
18.26M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-35.66M